NCT03303716 ASXL-Related Disorders Natural History Study
| NCT ID | NCT03303716 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, Los Angeles |
| Condition | Bohring-Opitz Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2017-09-20 |
| Primary Completion | 2037-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2017-09-20 with a primary completion date of 2037-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A registry focused on the natural history, management and treatment of patients with Bohring-Opitz Syndrome (ASXL1), Shashi-Pena Syndrome (ASXL2) and Bainbridge-Ropers Syndrome (ASXL3).
Eligibility Criteria
Inclusion Criteria: * Clinical or molecular diagnosis of an ASXL related disorder Exclusion Criteria: * No clinical or molecular diagnosis of an ASXL related disorder
Contact & Investigator
Wen-Hann Tan, BMBS
PRINCIPAL INVESTIGATOR
Boston Children's Hospital
Frequently Asked Questions
Who can join the NCT03303716 clinical trial?
This trial is open to participants of all sexes, studying Bohring-Opitz Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03303716 currently recruiting?
Yes, NCT03303716 is actively recruiting participants. Contact the research team at ASXL-CHROMATIN-REGISTRY@mednet.ucla.edu for enrollment information.
Where is the NCT03303716 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT03303716 clinical trial?
NCT03303716 is sponsored by University of California, Los Angeles. The principal investigator is Wen-Hann Tan, BMBS at Boston Children's Hospital. The trial plans to enroll 200 participants.